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Phosphoinositides are small phospholipids that control diverse cellular downstream signaling events. Their spatial and temporal avail-
ability is tightly regulated by a set of specific lipid kinases and phosphatases. Congenital muscular dystrophies are hereditary disorders
characterized by hypotonia and weakness from birth with variable eye and central nervous system involvement. In individuals exhibit-
ing congenital muscular dystrophy, early-onset cataracts, and mild intellectual disability but normal cranial magnetic resonance imag-
ing, we identified bi-allelic mutations in INPP5K, encoding inositol polyphosphate-5-phosphatase K. Mutations impaired phosphatase
activity toward the phosphoinositide phosphatidylinositol (4,5)-bisphosphate or altered the subcellular localization of INPP5K. Down-
regulation of INPP5K orthologs in zebrafish embryos disrupted muscle fiber morphology and resulted in abnormal eye development.
These data link congenital muscular dystrophies to defective phosphoinositide 5-phosphatase activity that is becoming increasingly
recognized for its role in mediating pivotal cellular mechanisms contributing to disease.Introduction
Congenital muscular dystrophies (CMDs) are clinically
and genetically heterogeneous inherited disorders in
which muscle weakness typically manifests at birth or in
infancy.1 Delayed motor milestones, poor motor abilities,
and joint or spinal rigidity are often the presenting fea-
tures. Muscle weakness may remain stable or deteriorate
over time. Complications include contractures, spinal de-
formities, and respiratory compromise. Cardiac involve-
ment, cognitive impairment, white matter and structural
abnormalities of the brain, seizures, and eye abnormalities
may occur depending on the genetic cause. For example,
early cataracts, cerebellar atrophy, and variable intellec-
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structural muscle pathology (dense perinuclear membra-
nous structures).2–4 Most CMDs are inherited in an
autosomal-recessive manner with the exception of de
novo dominant inheritance in CMDs caused by LMNAmu-
tations (MIM: 613205) and some cases of Ullrich CMD
(MIM: 254090). Mutations occur in genes encoding
structural proteins of the extracellular matrix, enzymes
catalyzing protein glycosylation, and proteins of the endo-
plasmic reticulum (ER) and nuclear envelope.5 Mutations
can be identified in 25%–50% of CMD-affected case sub-
jects,6 suggesting the existence of unidentified additional
genes harboring mutations causing CMD and underscor-
ing the need for ongoing investigation into the genetic
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Phosphatidylinositol (PtdIns) is a membrane phospho-
lipid that can be reversibly phosphorylated at the 3, 4,
and5positions of the inositol ring. Resultingphosphoinosi-
tides provide the basis for the synthesis of the second mes-
sengers diacylglycerol and inositol (1,4,5)-trisphosphate
(Ins(1,4,5)P3, IP3), which mobilize intracellular calcium
and activate protein kinase C.7 Moreover, through interac-
tions between their phosphorylated head groups and pro-
tein modules, phosphoinositides recruit proteins to the
cytosolic leaflet of membrane bilayers where they regulate
multiple processes including the assembly of signaling scaf-
folds, biogenesis of transport vesicles, endocytosis and secre-
tion, actinnucleation,microtubuledynamics, and transport
of ions and metabolites.8–11 The spatial and temporal con-
trol of the presence of each phosphoinositide at plasma
and organelle membranes12 is ensured by the action of ki-
nases and phosphatases that are differentially located on
specificmembranes.13 The relevanceof properphosphoino-
sitidemetabolism for cell and organ function is emphasized
by the growing number of human diseases resulting from
mutations in genes encoding enzymes that catalyze inter-
conversion from one phosphoinositide to another.14While
such mutations have been identified in other inherited
neurological andneuromuscular disorders, includingoculo-
cerebrorenal syndrome of Lowe (MIM: 309000),15 lethal
congenital contractural syndrome type 3 (MIM: 611369),16
X-linked myotubular myopathy (MIM: 310400),17 and
hereditary polyneuropathies (MIM: 601382, 604563,
611228),18–21 no phosphoinositide metabolizing enzymes
have been directly linked to CMD. Here we report that mu-
tations in the gene encoding inositol polyphosphate-5-
phosphatase K, INPP5K, cause a distinct form of CMD.Material and Methods
Study Participants
The study population included 64 index case subjects and addi-
tional affected and unaffected family members who were referred
to our laboratory for SIL1 (MIM: 608005) mutation screening for
suspected MSS. None of these individuals carried heterozygous
or bi-allelic SIL1 variants with predicted or known pathogenicity.
Thirty-five affected individuals presented with both early-onset
cataracts and skeletal muscular disease and occasionally one or
several additional symptoms or signs (most commonly ataxia,
cerebellar atrophy, hypotonia, motor delay, intellectual disability,
somatic growth retardation, spasticity, seizures, and micro-
cephaly). Twenty-nine index case subjects exhibited only one of
either early cataracts or skeletal muscular disease, always com-
bined with one or more aforementioned additional symptoms
and signs. The study was conducted in accordance with national
legislations and was approved by institutional review boards in
Munich, London, Newcastle, and at the NIH. Informed consent
was obtained from the probands or their legal guardians.
Reagents
If not stated otherwise, reagents were obtained from Sigma-
Aldrich. Sequences of oligonucleotide primers (Metabion) used
in this study are available upon request.524 The American Journal of Human Genetics 100, 523–536, MarchWhole-Exome Sequencing
The index case subject of family A (II.3) underwent whole-exome
sequencing on a Genome Analyzer HiSeq 2000 system (Illumina)
after in-solution enrichment of exon and flanking intron se-
quences (SureSelect Human all Exon 50Mb kit v4; Agilent) and in-
dexing of samples for multiplex-sequencing (Multiplexing Sample
Preparation Oligonucleotide Kit; Illumina). Read alignment was
performed with BWA v.0.5.8 to the human genome assembly
hg19. Single-nucleotide variants and small insertions and dele-
tions were called with SAMtools v.0.1.7. Variant annotation was
performed with custom Perl scripts, integrating data from
dbSNP135 and the UCSC Genome Browser Known Genes track.
We excluded all nongenic, intronic (other than canonical splice
sites), and synonymous variants, HapMap single-nucleotide poly-
morphisms (SNPs) present in dbSNP135 with an average heterozy-
gosity greater than 0.02, and variants present in >15 of >7,000
in-house exomes from individuals with unrelated diseases. Next,
because a recessive disease model and a common ancestral allele
(based on parental consanguinity) were expected, we gave priority
to homozygous variants.
Mutation Detection in Additional Families
The coding exons and flanking intron regions of INPP5K
(GenBank: NM_016532.3) were searched for mutations by Sanger
sequencing of DNA samples obtained from additional index case
subjects included in the study population. Oligonucleotide
primers for PCR amplification and sequencing were designed us-
ing Primer3 software based on the Human Genome Browser
genomic sequence of INPP5K. PCR products were sequenced using
the BigDye Terminator v.3.1 Ready Reaction Cycle Sequencing Kit
(Applied Biosystems) and capillary electrophoresis and detection
on a 3730 DNA Analyzer (Applied Biosystems).
Expression Constructs
Human INPP5K cDNA was amplified from human skeletal muscle
mRNA and cloned in pAcGFP-C1 (for mammalian expression) and
pGEX-4T-2 (for bacterial expression). INPP5Kmutants were gener-
ated by site-directed mutagenesis22 and verified by sequencing.
The expression vector for the ER marker mCherry-Sec61b (Addg-
ene plasmid #49155) was a gift from Gia Voeltz.23
Cell Culture and Transfection
COS-7 cells were cultured in Dulbecco’s Modified Eagle’s medium
(DMEM) containing 10% fetal calf serum, 2 mM glutamine,
40 U/mL penicillin, and 0.04 mg/mL streptomycin. Transfection
of COS-7 cells for live cell imaging was performed on 80%
confluent cells plated on 35-mm glass bottomed dishes (MatTek)
using Lipofectamine 2000 (Invitrogen) and constructs for GFP-
INPP5K and mCherry-Sec61b.
Fluorescence Microscopy
Live COS-7 cells cotransfected with GFP-tagged wild-type and
mutant INPP5K and mCherry-Sec61b constructs were examined
by fluorescence microscopy using a 3i-Marianas spinning disc
confocal microscope (Intelligent Imaging Innovations). All con-
structs were transfected and imaged simultaneously in a single
experiment. Ten to 15 random image fields were acquired at
403magnification for each construct and 60–120 transfected cells
per construct were assigned to one of three phenotypes by an
investigator blind to the INPP5K genotype: reticular ER-like stain-
ing, punctate or partial ER-like staining, and diffuse cytosolic2, 2017
staining. For whole-mount immunofluorescence staining, zebra-
fish embryos were fixed in 4% paraformaldehyde in phosphate-
buffered saline (PBS) at 4C overnight and blocked for 1 hr at
room temperature (RT) in 5% horse serum in PBS, 0.1% Tween-
20 before incubation overnight at 4C with primary antibodies
mouse anti-slow muscle myosin heavy chain (slow MyHc, clone
F59, Developmental Studies Hybridoma Bank [DSHB]; 1:50) and
mouse anti-fast muscle myosin heavy chain (fast MyHc, clone
F310, DSHB; 1:200). Incubation with secondary antibody Alexa
Fluor 488-conjugated goat anti-mouse immunoglobulin G (IgG)
(Thermo Fisher Scientific; 1:200) was performed for 1 hr at RT.
Images were captured with a Nikon A1R confocal microscope
(Nikon).
Measurement of INPP5K Phosphatase Activity
Wild-type and mutant GST-tagged full-length INPP5K was ex-
pressed in BL21 pLysS cells and purified on GSA beads (Thermo
Fisher Scientific) in assay buffer (50 mM Tris-HCl [pH 7.5],
150 mM NaCl, 10 mM MgCl2) plus 1% Triton X-100 and EDTA-
free protease inhibitors (Roche Diagnostics). After washing,
aliquots of beads were run on Coomassie gels to determine the
abundance of full-length fusion proteins. Beads bearing equal
amounts of fusion proteins were incubated in assay buffer con-
taining 135 mM PtdIns(4,5)P2diC8, and free phosphate was
measured using the Malachite Green assay kit (Echelon Biosci-
ences). Results of three independent experiments were presented
as mean 5 standard deviation. To minimize variability between
purifications, all constructs were freshly prepared and purified in
parallel for each experiment, and beads used in the assay were af-
terward run on Coomassie gels to confirm equal protein loading.
Structural Model of INPP5K
We modeled INPP5K structure by threading INPP5K sequence on
the closest available orthologous crystal structures, OCRL (cata-
lytic domain, PDB: 4CMN) and NDP52 (SKICH domain, PDB:
3VVW), using the Phyre2 server.24
Zebrafish Husbandry and Observation
We used the golden strain (slc24a5b1/þ) of zebrafish (Zebrafish
International Resource Center). Larvae were raised and staged as
described.25 Video recordings of embryos were captured using a
CMLN-13S2M camera (ClearView Imaging) mounted to a Leica
stereomicroscope (Leica). Light microscopy images were taken
with a Leica dissection stereomicroscope equipped with a DFC
420C Leica digital camera (Leica). Touch-evoked swimming
response was elicited by touching the embryos with a pipette
tip. Measurements of the eye diameter and the head diameter (dor-
sal-ventral axis) were taken and a ratio between the two was calcu-
lated. One-tailed Student’s t test was used to assess statistical
significance.
Antisense Morpholino Oligonucleotide Knockdown
Antisense morpholino oligonucleotides (MOs) were purchased
from Gene Tools. The MOs were designed based on the
sequence of the zebrafish INPP5K orthologs inpp5ka (GenBank:
XM_005157623.3) and inpp5kb (GenBank: XM_005155275.3).
We established splice-blocking MOs directed against the splice
donor site of intron 4 of inpp5ka (50-CAGACTGAAGAGGAGCAG
CATTCAA-30) and against the splice donor site of intron 4 of
inpp5kb (50-TAGACTGGGACACATTTGCTCAGGT-30). The Gene
Tools standard control MO (50-CCTCTTACCTCAGTTACAATTThe AmeriTATA-30) was used as a negative control for the effects of MO
injections. Embryos were injected with control MO (5 ng) or
both anti-INPP5K MOs (2.5 ng of inpp5ka MO, 5 ng of inpp5kb
MO) and efficient gene knockdown was verified by RT-PCR. 29%
of non-injected embryos, 37% of embryos injected with control
MO, and 64% of inpp5kaþinpp5kb double-knockdown morphants
were dead. Five independent MO injection experiments were
performed for each MO and at least 500 injected embryos were
evaluated for each MO.Results
Bi-allelic Mutations in INPP5K Are Associated with CMD
with Early-Onset Cataracts
A consanguineous Bangladeshi multiplex family with two
affected and four unaffected children (family A; Figure 1A)
presented the possibility of locating the disease locus
by linkage analysis. Genome-wide genotyping with
approximately 300,000 SNP markers revealed two hits on
chr10q11.22–10q21.1 and chr17p13.3–17p13.2 with a
maximum LOD score of 2.27 (Figure S1). The 5.58-Mb re-
gion of interest on the short arm of chr17 was further
supported by the results of short tandem repeat marker
genotyping in 12 out of 43 additional families suitable
for haplotype analysis. A subgroup of these families was
also tested for the potential chr10 locus; 1 out of 22 fam-
ilies was compatible with localization of so far unknown
CMD mutations on chr10 (data not shown).
We next performed whole-exome sequencing on the in-
dex case subject of family A. The average read depth was
129 with 94% of the targeted regions covered at least 20-
fold. After read alignment, variant calling, annotation,
and filtering, we focused our analysis on non-synonymous
homozygous variants located in the regions of interest
on chr10q and chr17p and reduced potential disease-
causing variants to two changes on chr17p. A c.149T>C
(p.Ile50Thr) variant in INPP5K (GenBank: NM_016532.3)
(Figures 1A and S2) was a non-conservative change,
affected a strictly conserved amino acid, was predicted
to interfere with normal protein function by bio-
informatic algorithms (Table S1), and was absent from
databases (dbSNP146, Exome Aggregation Consortium
[ExAC], and >7,000 in-house exomes). The second
variant, c.1156C>G (p.Leu386Val) in SLC52A1 (GenBank:
NM_017986.3), was considered unlikely as it resulted in a
conservative change of a non-conserved amino acid, was
predicted benign by bioinformatic algorithms, and had a
MAF of up to 0.5% in ExAC subpopulations.
We obtained further evidence for a causative role of
INPP5K mutations when extending mutation screening
to the 12 families homozygous for the chr17p locus or
compatible with linkage to this region. Sanger sequencing
of the INPP5K coding region yielded bi-allelic mutations in
six pedigrees (families B–G, Figures 1A and S2). Sanger
sequencing of 21 isolated case subjects with non-consan-
guineous parents resulted in the identification of one indi-
vidual carrying bi-allelic INPP5K mutations (family H,can Journal of Human Genetics 100, 523–536, March 2, 2017 525
Figure 1. INPP5K Mutations in Families with CMD and Cataracts
(A) Pedigrees of families with identified homozygous or compound heterozygous INPP5Kmutations. Squares represent males and circles
represent females. Filled symbols represent affected individuals. INPP5K genotypes of individuals from whom a DNA sample was avail-
able are given below the pedigree symbols. Unaffected individuals were either heterozygous carriers or homozygous for the wild-type
allele. þ/þ indicates homozygous for mutation; þ/ indicates heterozygous; / indicates homozygous for wild-type.
(B) Schematic representation of INPP5K and distribution of mutations. Amino acid numbering is shown below. Abbrevaitions: 5-phos-
phatase, inositol 5-phosphatase domain; SKICH, skeletal muscle and kidney-enriched inositol phosphatase carboxyl homology domain.
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Figures 1A and S2). Altogether, we found four different
INPP5K mutations consisting of three missense mutations
(c.149T>C [p.Ile50Thr], c.899A>G [p.Tyr300Cys], and
c.1088T>C [p.Ile363Thr]) and one in-frame deletion
(c.881_883delCCT [p.Ser294del]) (Figure 1B). Whenever
DNA from family members was available, we observed
that the disease segregated with recessive inheritance of
the INPP5K mutations (Figure 1A).
In keeping with INPP5K mutations causing a condition
affecting skeletal muscle and eye, we confirmed presence
of mouse INPP5K in these tissues (Figure S3A). INPP5K is
a 12-exon gene encoding a 448-amino acid protein con-
taining a 5-phosphatase domain.26 An additional C-termi-
nal SKICH motif has been linked to targeting of INPP5K to
the ER membrane;27 indeed, we observed colocalization
of INPP5K with ER membranes in COS-7 cells cotrans-
fected with GFP-INPP5K and the ER membrane marker
mCherry-Sec61b (Figure S3B). The three missense muta-
tions identified in our study affected strictly conserved
amino acids and were predicted as deleterious to protein
function or disease causing by 5/5 bioinformatic algo-
rithms (Table S1). The c.149T>C (p.Ile50Thr) and
c.1088T>C (p.Ile363Thr) variants were not observed in
public databases (dbSNP146, ExAC) or in in-house exome
datasets, which altogether allow interrogation of exome
data of about 70,000 individuals. For the c.899A>G
(p.Tyr300Cys) and c.881_883delCCT (p.Ser294del) vari-
ants, there were single heterozygous samples among the
60,000 individuals in ExAC (MAF 0.0000082; highest
observed MAF in a subpopulation 0.00012 [East Asians]
for p.Tyr300Cys and 0.00015 [Finnish Europeans] for
p.Ser294del). Both of these samples probably represent car-
riers unaffected by INPP5K mutation-associated disease.
INPP5K Mutations Result in a Consistent and
Recognizable Phenotype
All individuals with identified bi-allelic INPP5K mutations
presented with a homogeneous clinical picture including
both CMD and early-onset cataracts, usually with mild
intellectual disability. The cerebellum appeared normal
(Table 1, Figures 2A–2C). Notably, linkage to chr17 or
INPP5K mutations were excluded in 29 families and iso-
lated case subjects presenting with an incomplete pheno-
type, i.e., either skeletal muscular disease or early cataracts
together with variable additional clinical manifestations
(mainly polyneuropathy, cerebellar atrophy, or other brain
malformations). Detection of INPP5K mutations in only 8
out of 35 families and index case subjects with combined
skeletal muscular disease and early-onset cataracts might
be explained by INPPK variants that are missed by
commonly applied diagnostic strategies (e.g., genomic re-
arrangements or small deep intronic or regulatory vari-
ants), alternative effects of synonymous variants or locus
heterogeneity.
The presenting symptoms were early bilateral lens
opacities, muscle weakness from birth, motor or global
developmental delay, or abnormal gait noted soon afterThe Ameriindependent walking had been acquired. Although
affected individuals usually reached their motor mile-
stones late, they all eventually acquired independent
walking and muscle weakness, which was generally most
prominent in proximal lower limb muscles, stabilized for
several years. During the course of the disease, motor capa-
bilities appeared to deteriorate, and (except for family A)
older cases (families D, F, H) had lost ambulation (Table 1).
Five subjects developed respiratory compromise. No facial
or oculomotor weakness or cardiac involvement was
observed. Creatine kinase values were invariably markedly
elevated (mean 37 of the upper normal limit, range 33
to 314). Electromyography (EMG) results in three affected
individuals were in accordance with a myopathic process
while motor nerve conduction studies did not demon-
strate substantial abnormalities. Muscle magnetic reso-
nance imaging (MRI) in individual II.1, family H revealed
progressive degenerative myopathy (Figures 2D and 2E).
Cognitive deficits, usually mild, were recorded in eight
probands while four individuals had normal intelligence.
A few affected individuals had additional symptoms
including contractures, scoliosis, spinal rigidity, micro-
cephaly, hyperlaxity in finger joints, intention tremor, sei-
zures, or hypogonadism. No white matter and structural
abnormalities of the brain were recorded except for II.1
(family H) who had widened inner and outer cerebrospinal
liquor spaces but no focal alteration (Figure 2C) along with
mild cognitive impairment.
Muscle biopsies had been taken previously from nine in-
dividuals with INPP5K mutations for diagnostic purposes
(Table 1). Muscle pathology was largely nonspecific,
showing variable degrees of dystrophic features, including
increased range of muscle fiber size with small and hyper-
trophic fibers, muscle fibrosis, excess adipose tissue, occa-
sional fibers with internal nuclei, rare necrotic fibers, and
a few basophilic (regenerating) fibers (Figures 2F, S4A,
and S4B). There were no abnormalities of blood vessels, in-
flammatory changes, or group atrophy. Three biopsies
showed variable numbers of vacuolated muscle fibers (Fig-
ures S4C–S4E). Some vacuoles presented with increased
acid phosphatase and non-specific esterase activity or as
rimmed vacuoles (Figure S4E). The distribution of fiber
types was sometimes uneven with several fascicles display-
ing a type 1 or type 2 predominance. Oxidative enzyme
localization was generally normal with no or only rare
areas devoid of activity. No inclusions or excess storagema-
terial were seen. Immunohistochemistry for dystrophin,
sarcoglycans, a-dystroglycan, and laminin-a2 (merosin)
was normal (Figures S4F and S4G). In some biopsies, cyto-
plasmic labeling for a-B crystallin, VCP, and p62 as well as
developmental and fetal myosin was observed in a variable
proportion of fibers. Electron microscopy was performed
on two biopsies (II.3 from family B and II.1 from
family H) and revealed several fibers with pronounced
reduction of myofibrils and disrupted Z line material. Elec-
tron microscopy further confirmed the presence of occa-
sional small vacuoles (Figure S4H), sometimes filled withcan Journal of Human Genetics 100, 523–536, March 2, 2017 527
Table 1. Clinical Features of Individuals with Bi-allelic INPP5K Mutations
Family Subject Sex Age
Ethnic
Origin Consanguinity
INPP5K
Variant
Initial Presenting
Symptom (at Age)
Cataracts (Age
at Diagnosis) Hypotonia
Delayed
Motor
Milestones
A IV.3 F 21 y Bangladesh þ p.[Ile50Thr];
[Ile50Thr]
motor developmental
delay (15 m)
þ (6 y) þ þ
IV.4 F 22 y motor developmental
delay (15 m)
þ (4 y) þ þ
B II.3 M 8.5 y Bangladesh þ p.[Ile50Thr];
[Ile50Thr]
global developmental
delay (10 m)
þ (12 m) þ þ
C II.1 M 11 y Bangladesh þ p.[Ile50Thr];
[Ile50Thr]
cataracts (4 y) þ (4 y)  
D III.1 F 35 y Pakistan  p.[Ile50Thr];
[Ile50Thr]
walking
difficulty (2 y)
þ (3 y) þ þ
III.6 M 25 y cataracts (1.5 y) þ (1.5 y) þ 
E II.1 F 9.5 y Pakistan þ p.[Ile50Thr];
[Ile50Thr]
global developmental
delay (2.5 y)
þ (5 y) þ þ
F II.1 F 37 y Brazil – p.[Ser294del];
[Ile363Thr]
hypotonia (birth) þ (6 m) þ þ
II.2 M 35 y hypotonia (birth) þ (6 m) þ þ
G II.1 M 7 y Pakistan þ p.[Ile50Thr];
[Ile50Thr]
hypotonia, motor
delay (birth)
þ (early
childhood)
þ þ
II.2 F 6 y hypotonia, motor
delay (birth)
þ (early
childhood)
þ þ
H II.1 F 41 y Germany  p.[Tyr300Cys];
[Tyr300Cys]
motor developmental
delay (1 y)
þ (5 y) þ þ
Abbreviations are as follows: F, female; M, male; m, month(s); y, year(s); þ, present; , not present; NA, not available; ND, not determined; CK, serum creatine
kinase; P>D, proximalmusclesmore severely affected than distal muscles; LL>UL, lower limbmusclesmore severely affected than upper limbmuscles. Bestmotor
ability: 0, normal walking, running, and jumping; 1, normal walking, no running and jumping; 2, walks longer distances unsupported, abnormal gait; 3, walks a few
steps unsupported, requireswalking aids orwheelchair for longer distances; 4,walks onlywithwalking aids or useswheelchairmost of the time; 5,wheelchair bound.myelin-like whorls as seen in rimmed vacuoles. In one of
the two biopsies studied by electron microscopy (II.3, fam-
ily B), several myonuclei had dense peripheral heterochro-
matin or were filled with osmiophilic material. Some of
these abnormal nuclei also appeared to have an incom-
plete nuclear membrane or were surrounded by a dense
membrane-like structure (Figure S4I).
INPP5K Mutants Alter Subcellular Localization or Impair
Phosphatase Activity for PtdIns(4,5)P2
Immunoblotting of protein preparations from C2C12 and
COS-7 cells transfected with expression vectors for INPP5K
wild-type and mutants showed no major effect of muta-
tions on protein levels (Figures S5A and S5B). The mutants
p.Ile50Thr, p.Ser294del, and p.Tyr300Cys showed com-
plete or partial perinuclear localization when overex-
pressed as GFP-fusion proteins in COS-7 cells (Figure 3A),
largely indistinguishable from the wild-type protein,
which is regularly located at the ER (Figures 3A and S3B
and Gurung et al.27). The p.Ile363Thr mutant affecting
the SKICH motif, however, displayed a striking ten-
dency for a more diffuse distribution in transfected cells
(Figure 3A).528 The American Journal of Human Genetics 100, 523–536, MarchINPP5K has been reported to dephosphorylate both
PtdIns(4,5)P2 and PtdIns(3,4,5)P3, at the D-5 position, with
marked preference for PtdIns(4,5)P2.
28 We therefore per-
formed in vitro measurement of catalytic activity using
full-length recombinant wild-type INPP5K and mutants
affecting the phosphatase domain (p.Ile50Thr, p.Ser294del,
p.Tyr300Cys) togetherwithPtdIns(4,5)P2diC8as a substrate.
We found that the disease-related phosphatase domainmu-
tants and an artificial catalytically deadmutantp.Asp310Gly
displayed reduced enzymatic activity (Figure 3B). While
p.Tyr300Cys showed strongest impairment with activity
almost as low as the catalytically dead control, the two other
mutants had retained a variable degree of residual catalytic
activity. Modeling of INPP5K mutants on the crystal struc-
ture of the OCRL catalytic domain showed that the muta-
tions did not directly alter the predicted INPP5K catalytic
site (Figure 3C). Instead, they affected residues that were in
the folding core of the predicted crystal structure and may
therefore destabilize the overall shape of the phosphatase
domain, indirectly rendering the enzyme inactive.
Throughmetabolizing PtdIns(3,4,5)P3, INPP5K is thought
to interfere with recruitment and activation of effector pro-
teins such as the serine/threonine kinases Akt that regulate2, 2017
Muscle
Weakness/
Atrophy
Best
Motor
Ability
CK (3 Upper
Normal
Limit) EMG
Muscle
Biopsy
Intellectual
Disability
Brain
Abnormality
Respiratory/
Cardiac
Involvement Other Findings
þ/NA, P > D,
LL > UL
2 34.5 ND dystrophic mild  / contractures (ankle), scoliosis
þ/NA, P > D,
LL > UL
2 38.5 ND ND moderate ND þ/ contractures (ankle), scoliosis
þ/, P > D,
LL > UL
2 35 ND myopathic moderate  þ/ S. aureus sepsis and
meningitis at age 4 m
þ/NA, P > D,
LL > UL
2 34.5 ND ND mild  þ/ 
þ/, P > D,
LL > UL
4 34 ND myopathic  ND þ/ spinal rigidity, contractures
þ/NA, P > D,
LL > UL
4 ND ND ND  ND / spinal rigidity, hyperlaxity
in finger joints
þ/þ 2 310 ND myopathic mild  / intention tremor, microcephaly
(mild)
þ/þ, P > D 4 34 myopathic dystrophic mild  / microcephaly, kyphosis,
contractures (knee, ankle)
þ/þ, P > D 4 33 ND dystrophic mild  / microcephaly, kyphosis, con-
tractures (knee, ankle), seizures
þ/þ, P > D,
LL > UL
2 314 myopathic myopathic   / 
þ/þ, P > D,
LL > UL
2 ND ND myopathic   / 
þ/þ, P > D 4 312 myopathic vacuolar
myopathy
mild mild global
brain atrophy
þ/ hypogonadismmany signaling pathways.29 INPP5K overexpression has
been reported to attenuate Akt phosphorylation in response
to IGF-II and insulin stimulation.30,31 However, we noted
no differences in Akt phosphorylation between IGF-II-
treated human skin fibroblasts from individuals with the
p.Ile50Thr mutation and control subjects (Figure S6). This
discrepancy is probably related to the reported low activity
of INPP5K toward PtdIns(3,4,5)P3.
28 In line with this inter-
pretation, we observed no INPP5K activity in the malachite
green phosphatase assay with 135 mM PtdIns(3,4,5)P3diC8
as substrate (data not shown). It seems possible that the
low activity of INPP5K toward PtdIns(3,4,5)P3 may hamper
reproducible detection of downstream effects in different
experiments.
Zebrafish inpp5kaþinpp5kb Knockdown Morphants
Replicate Aspects of the Human Phenotype
We identified two orthologs of INPP5K in zebrafish,
inpp5ka and inpp5kb. Treatment with specific morpholi-
nos reduced inpp5ka and inpp5kb expression at 48 hr
post fertilization (hpf) (Figure S7). Macroscopically,
inpp5kaþinpp5kb MO-injected embryos displayed altered
tail morphology (curled and shortened tails, Figure 4A)The Ameriand severely impaired swimming and touch-evoked
escape response (data not shown), whereas control
MO-injected embryos and non-injected embryos were
largely indistinguishable. inpp5kaþinpp5kb morphants
also showed a reduction in the size of their eyes
compared to non-injected and control MO-injected
embryos (Figure 4B). Histologically, we observed abnor-
malities of skeletal muscle morphology in inpp5kaþ
inpp5kb-depleted embryos. Immunostaining of morphants
for slow-twitch and fast-twitch fibers showed disruption
of the regular chevron shape of somites, curvature and
distortion of both fiber types, and abnormal myosepta
(Figure 4C). In contrast, development of neuromuscular
junctions progressed normally up to 48 hpf in inpp5ka-
þinpp5kb-deficient zebrafish embryos (Figure S8).
INPP5K Mutants Do Not Alter ER-Stress Response and
BiP Interaction
We noted that there were certain similarities between
INPP5K-associated disease and MSS, both in terms of
clinical features (early-onset cataracts, skeletal muscle
involvement, variable intellectual disability2) and muscle
pathology (vacuolation and dense membranous structurescan Journal of Human Genetics 100, 523–536, March 2, 2017 529
Figure 2. Clinical, Imaging, and Muscle
Biopsy Findings of Individuals with Bi-
allelic INPP5K Mutations
(A) Individual II.1, family G, at age 7 years.
Note mild atrophy of the shoulder girdle
muscles and posterior compartment of
the thighs.
(B) Individual II.1, family H, at age 41 years.
Standing independently was possible only
with wide stance and the arms could not
be lifted above the head (maximum arm
elevation 45) due to proximal upper and
lower limb weakness. Hunchback and
markedatrophyof scapuloperoneal anddor-
sal proximal leg muscles were noted.
(C) Individual II.1, family H, at age 25 years.
Sagittal T1-weighted, contrast-enhanced
cranial MRI revealed mild global brain atro-
phynot appropriate for age but normal cere-
bellar architecture.
(D) Individual II.1, family H, at age 41 years.
Whole-body T1-weighted MRI showed
marked muscle atrophy and fatty degenera-
tion, predominantly in proximal arm and
leg muscles.
(E) Individual II.1, family H, at age 25 years
(top) and age 41 years (bottom). Cross-
sectional T1-weighted MRI of the thighs
revealed progressive muscle atrophy and
fatty degeneration,most severe inM. vastus
medialis, M. rectus femoris, M. semimem-
branosus, and adductor muscles.
(F) Muscle biopsy from individual II.2, fam-
ily G, taken at age 3 years (site of biopsy not
documented). H&E stain showed marked
variation in fiber size, rounding of fibers,
increased endomysial collagen, and some
fatty degeneration. Scale bar represents
50 mm.associated with nuclei4). Moreover, INPP5K is located at
the ER27 and MSS is related to ER dysfunction,32,33 leading
to induction of the unfolded protein response (UPR), an ER
stress reaction.34 We therefore used quantitative prote-
omics to measure abundances of well-validated mamma-
lian UPR markers. However, we did not observe major
differences between skin fibroblasts from individuals
with bi-allelic INPP5K mutations and control individuals
(Figure S9). Very recently, INPP5K has been reported to
interact with BiP,35 a master regulator of ER functions
including the ER stress response.36 BiP is also involved in
MSS pathophysiology as its activity is controlled by the co-
chaperone SIL1,37 the proteinmutant inMSS.3,38 By copre-
cipitation, we confirmed binding of wild-type INPP5K to
BiP, but disease-related INPP5K mutants bound equally
well (Figure S10).530 The American Journal of Human Genetics 100, 523–536, March 2, 2017INPP5K Does Not Have a Major
Impact on Autophagy
Some muscle biopsy findings in indi-
viduals with INPP5K mutations (vacu-
oles, sometimes rimmed, and accumu-
lation of a-B crystallin and p62), the
role of autophagy in the pathogenesisof skeletal muscular disease,39–43 and the function of
PtdIns(4,5)P2
44andINPP5K45 in the regulationofautophagy
promptedus tostudy this intracellulardegradationsystemin
a muscle biopsy (Figure S11A) and skin fibroblasts (Figures
S11B and S11C) from individuals with INPP5K mutations.
However, LC3B immunoblotting and immunofluorescence
staining as well as measurement of LC3B turnover and p62
levels in fibroblasts treated with the autophagy inducer
rapamycin and the lysosomal inhibitor bafilomycin A1 did
not reveal specific effects of different INPP5K genotypes.Discussion
We identified bi-allelic missense and in-frame deletion
mutations in INPP5K in eight families with a syndrome
AC
B
Figure 3. Structural and Functional Con-
sequences of INPP5K Mutants
(A) Subcellular localization of INPP5K mu-
tants. Live COS-7 cells cotransfected with
the ER marker mCherry-Sec61b (red) and
GFP-tagged wild-type or mutant INPP5K
constructs were imaged and assigned to
one of three categories. Phosphatase
domain mutants did not have a strong ef-
fect on protein targeting to the ER, appear-
ing substantially like the wild-type fusion
protein. Conversely, the p.Ile363Thr muta-
tion in the SKICH domain caused the
GFP signal to become punctate or diffuse
cytosolic in almost all cells. At least 60
randomly selected cells were assessed per
INPP5K construct in one experiment by
an observer unaware of the INPP5K geno-
type. Scale bars represent 50 mm.
(B) GST-INPP5K phosphatase activity on
135 mM PtdIns(4,5)P2diC8. Disease mu-
tants affecting the phosphatase domain
interfere with enzyme activity. The variant
p.Asp310Gly is an artificial mutant pre-
dicted to result in a catalytically dead pro-
tein through altering the active center.
Bars represent mean values of three inde-
pendent experiments and error bars repre-
sent standard deviations.
(C) Model of predicted INPP5K crystal
structure (Phyre2). Mutated residues (yel-
low) were located outside the active center
of the enzyme (red) but appeared to affect
residues in the folding core of the 5-phos-
phatase domain and in the SKICH motif.consisting of CMD, early-onset cataracts, andmild intellec-
tual disability. The pathogenic relevance of identified
INPP5K variants is supported by segregation with disease
in several families, restriction to case subjects or extremely
low prevalence in control subjects, impaired phosphatase
activity for PtdIns(4,5)P2, and aberrant subcellular localiza-
tion of mutant protein. The absence of INPP5K truncation
mutations with clear loss of function may imply that
variants in our series represent hypomorphic alleles;
this is further supported by embryonic lethality in homo-
zygous constitutive Inpp5k knockout mice.46 Replica-
tion of the human phenotype in zebrafish inpp5kaþ
inpp5kb double morphants, which manifested skeletal
muscle and ocular abnormalities, lends further credence
to this concept, as targeting gene expression by morpholi-
nos usually does not result in complete deficiency of the
respective proteins.
The clinical presentation of individuals with bi-allelic
INPP5K mutations was relatively homogeneous. The
most salient features were bilateral cataracts that required
surgery in the first years of life, predominantly proximal
muscle weakness from birth, delayed motor or global
development, first followed by rather stationary course of
the disease but later progression to loss of ambulation,
mild intellectual disability, and elevated serum CK levels.
Muscle biopsies of nine affected individuals revealedThe Amerilargely nonspecific dystrophic features consisting of varia-
tion in fiber size, fatty replacement, and fibrosis. Clinical
and muscle biopsy findings of similar cases have been re-
ported earlier,47,48 and in one of these families we identi-
fied INPP5K mutations (family F). High serum CK levels
and muscle histology were consistent with CMD rather
than a form of clinically similar congenital myopathy,
which typically features normal or near-normal serum
CK concentrations and histological evidence of develop-
mental or structural muscle changes.49 Muscle pathology
in inpp5kaþinpp5kb zebrafish morphants was also indica-
tive of skeletal muscle degeneration, again supporting a
muscular dystrophy in individuals with INPP5Kmutations
and reinforcing the view that zebrafish can be used to
model neuromuscular conditions.50
Although individuals with INPP5K mutations did not
have cerebellar atrophy and ataxia, there was a clear
phenotypic overlap with MSS (early cataracts, myopathy,
cerebellar atrophy, variable intellectual disability). Histo-
logical examination of three diagnostic muscle biopsies
from individuals with INPP5Kmutations showed vacuoles
in several myofibers, and electron microscopy of one bi-
opsy revealed dense membranous structures associated
with some myonuclei. Similar abnormalities have been re-
ported in MSS caused by SIL1 mutations2–4 and Sil1-defi-
cient mice.32 Since MSS is a disease of protein processingcan Journal of Human Genetics 100, 523–536, March 2, 2017 531
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Figure 4. Defects in Zebrafish inpp5kaþinpp5kb Double Morphants at 48 hpf
(A) Live embryos injected with control MO, inpp5kaMO, and inpp5kbMOor left untreated (non-injected). More than 95% of living non-
injected embryos and embryos injectedwith controlMO showed nomacroscopic abnormalities. Images for inpp5kaþinpp5kbmorphants
representmild (left, 15% of living embryos), moderate (middle, 24% of living embryos), and severe (right, 44% of living embryos) defects
in terms of length and curvature of tails. At least 150 living embryos were counted per condition. Scale bars represent 500 mm.
(B) Eye-to-head ratio of zebrafish embryos at 48 hpf. Eye diameter (white line) and head diameter (red line) were measured in the dorsal-
ventral axis and ratios were calculated. Scale bars represent 250 mm. Graphs represent mean values of ratios obtained with ten embryos
and error bars represent standard deviations. The statistical difference between non-injected and control MO-injected embryos and
inpp5kaþinpp5kb double morphants is indicated: n.s. indicates not significant, ***p < 0.001 (one-tailed Student’s t test).
(C)Whole-mount immunostainingsof zebrafishembryos at 48hpfusing antibodies against slowmusclemyosinheavychain (slowMyHc)
and fast muscle myosin heavy chain (fast MyHc). Images for inpp5kaþinpp5kbmorphants represent mild, moderate, and severe pheno-
types (from left to right) as staged macroscopically. inpp5kaþinpp5kb-deficient embryos displayed muscle fiber defects and loss of the
chevron shape of somites. The normal straight alignment of slow twitch muscle fibers was disrupted in inpp5kaþinpp5kb double knock-
downmorphants. Fibers appearedwavyanddeformationofmyoseptawas observed in severephenotypes (arrows). Staining for fast twitch
muscle fibers also showed distortion and defects of fibers and severe alterations of myosepta (arrows). Scale bars represent 50 mm.in the ER and since INPP5K is associated with ER mem-
branes and interacts with BiP,35 a master regulator of ER
functions,36 we considered a pathophysiological common-
ality of INPP5K-related disease with MSS. However, we
found no evidence for induction of the ER stress response
in skin fibroblasts from individuals with bi-allelic INPP5K
mutations and disease-causing INPP5K mutants did not
interfere with interaction with BiP, suggesting still other
mechanisms resulting in INPP5K-related disease.
Currently established disease mechanisms in CMD
include disturbed formation of the extracellular matrix,
impaired protein glycosylation, and defective phosphati-
dylcholine biosynthesis, as well as abnormalities of pro-
teins of the ER and nuclear envelope.5 Abnormalities of532 The American Journal of Human Genetics 100, 523–536, Marchphosphoinositide metabolism have not yet been described
in CMD but have been observed in several other neuro-
muscular conditions including non-dystrophic myotubu-
lar myopathy caused by mutations in MTM1, encoding
the phosphoinositide 3-phosphatase myotubularin.17
Phosphoinositide 5-phosphatases have not yet been impli-
cated in skeletal muscle disorders, but have been in a num-
ber of other conditions. One example is Lowe syndrome,
an X-linked disorder caused by OCRL mutations.15 Boys
with Lowe syndrome present with intellectual disability,
epileptic seizures, kidney problems, and congenital cata-
racts. While cataracts and intellectual disability are seen
in both Lowe syndrome and individuals with INPP5K mu-
tations, there are no abnormalities of the skeletal muscle in2, 2017
Lowe syndrome and individuals with INPP5K mutations
did not have kidney disease despite the strong expression
of INPP5K in this organ.26
Our data from phosphatase assays were in accordance
with earlier reports that INPP5K catalyzes the removal of
the 5-phosphate from PtdIns(4,5)P2.
28 All three disease-
related INPP5K mutants affecting the catalytic domain
showed significantly decreasedphosphoinositidephospha-
tase activity. Modeling of mutants on the known crystal
structure of the OCRL catalytic domain suggested that
they do not directly alter the catalytic site of the enzyme.
Instead, they are likely to change global folding of the phos-
phatase domain, rendering it disordered and non-func-
tional. The p.Ile363Thr mutant, which did not affect the
phosphatase domain, showed abnormal localization away
from the ER where wild-type INPP5K and the remaining
mutants were located. This result is in line with this partic-
ular mutation occurring in the C-terminal SKICH domain,
which is known to control INPP5K subcellular localiza-
tion27 most likely through binding to partner proteins.
Impaired enzymatic function of INPP5K mutants sug-
gested excess PtdIns(4,5)P2 in affected individuals’ cells.
PtdIns(4,5)P2 has been linked to a wide array of molecular
andcellular functions.As the substrate for receptor-regulated
phospholipaseC-mediatedhydrolysis, its cleavage generates
the secondary messengers Ins(1,4,5)P3 and diacylglycerol,
whichmobilize intracellular calciumand activate protein ki-
nase C.7 In growth factor-activated cells, phosphoinositide
3-kinase converts PtdIns(4,5)P2 into PtdIns(3,4,5)P3, which
is involved in the regulation of cell death, cell cycle, actin
polymerization, membrane ruffling, cell migration, and
secretion.10,51–53 As an intact phospholipid, PtdIns(4,5)P2
itself regulates membrane trafficking by recruiting protein
complexes to the plasma membrane and multiple intra-
cellular compartments.54,55 PtdIns(4,5)P2 functions extend
to actin polymerization and focal adhesion assembly,56
channel and transporter regulation,57,58 virus budding,59
exocytosis,60 phagocytosis,61 endocytosis,9,60 and endoso-
mal recycling62 as well as endolysosomal trafficking and
autophagosomal pathways.44,63
The role of PtdIns(4,5)P2 in autophagy was notable as
INPP5K has been linked to the control of autophagy in
Drosophila45 and some aspects inmuscle biopsies of individ-
uals with INPP5K mutations were consistent with autopha-
gic degeneration. However, we could not corroborate these
observations by studying LC3B turnover and p62 levels in
a muscle biopsy and skin fibroblasts from individuals with
INPP5K mutations. While further mechanisms related to
PtdIns(4,5)P2 will soon be tested for their relevance in
INPP5K pathophysiology, it is also possible that impaired
dephosphorylation of PtdIns(4,5)P2 is not the (most) rele-
vant aspect leading to disease, and other INPP5K substrates
or unknown functions might be more important. Although
we did not find differential regulation of Akt phosphoryla-
tion in IGF-II-stimulated cells from individuals with INPP5K
mutations, INPP5K appears to be involved in PtdIns(3,4,5)
P3-dependent regulation of insulin signaling and glucoseThe Amerihomeostasis in skeletal muscle.64 A recent study suggested
that INPP5K regulates myoblast differentiation through
the IGF-II-PI 3-kinase-Akt-mTOR pathway.30 There are dis-
crepancies concerning the effect of impaired INPP5K activ-
ity, leading to improved myoblast differentiation,30 con-
trasting with muscular dystrophy in individuals with
INPP5K mutations. However, although unexpected in an
autosomal-recessive condition, the mutant INPP5K species
may have acquired characteristics of a gain of abnormal
function. Despite these limitations of our study, leaving
the precise pathogenic mechanisms to be determined, we
have established compelling genetic evidence that INPP5K
is essential for skeletal muscle structure and function.Supplemental Data
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